



COCHAIRS:

Peter S. Nelson, Fred Hutchison Cancer Center, Seattle, WA

Elena Castro, Hospital Universitario 12 de Octubre, Madrid, Spain

Patrick G. Pilié, The University of Texas MD Anderson Cancer Center, Houston, TX

Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, MA

TUESDAY, JANUARY 20

Registration and Poster set-up

3:00 - 5:00 p.m. | Essex Foyer

Welcome and Opening Keynote Session

5:00 – 5:45 p.m. | Essex Ballroom

- | | |
|-----------|--|
| 5:00-5:10 | Welcome and Introduction
Peter S. Nelson, Fred Hutchison Cancer Center, Seattle, WA |
| 5:10-5:15 | Introduction of Keynote Speaker
Peter S. Nelson |
| 5:15-5:45 | Prostate Cancer Research 2026: The Best of Times, the Worst of Times
Francis S. Collins
Former Director of the National Institute of Health (NIH), Bethesda, MD |

Panel Session/Debate

5:45 p.m. 6:30 p.m. | Essex Ballroom

Moderator: *Eliezer Van Allen, Dana-Farber Cancer Institute, Boston, MA*

Topics:

- Can in vitro models adequately and accurately replace vertebrate animal systems for studies of prostate cancer?
- Why is advanced prostate cancer immune recalcitrant? What is missing from our understanding, and are there approaches on the horizon?
- For lineage “switch” after AR pathway ablation – why is this commonly neuroendocrine? Why not other lineages?

Panelists:

- Ana Aparicio, MD Anderson Cancer Center, Houston, TX
- Steven Balk, Beth Israel Deaconess Medical Center, Boston, MA
- Laura Sena, Johns Hopkins University, Baltimore, MD
- Adam Sharp, The Institute of Cancer Research, Sutton, England
- Jean-Philippe Theurillat, IOR - Institute of Oncology Research, Switzerland
- Ian Mills, University of Oxford, England, UK

**Short talks selected from proffered abstracts*

Lightning Talks Session I

6:30 p.m.-7:30 p.m. | Essex Ballroom

Session Chair: Eliezer Van Allen, DFCI, Elena Castro, Hospital Universitario 12 de Octubre

[Lightning Talk Session I Titles](#)

Poster Session A & Reception

7:30 p.m. – 9:30 p.m. | Staffordshire/ Essex North

WEDNESDAY, JANUARY 21

Continental Breakfast

7:00-8:00 a.m. | Essex Foyer

Plenary Session 1: AI in Prostate Cancer Research

8:00-10:15 a.m. | Essex Ballroom

Session Chair A: Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, MA

Session Chair B: Stephanie A. Harmon, National Institute of Health, Bethesda, MD

- 8:00-8:05 Introduction

- 8:05-8:25 **Therapeutic Discovery in the Digital Era**
 William R. Sellers
 Broad Institute, Cambridge, MA

- 8:25-8:45 **Do androids dream of prostate cancer research?**
 Eliezer M. Van Allen

- 8:45-9:05 **AI-based imaging biomarkers**
 Stephanie A. Harmon
 National Institute of Health, Bethesda, MD

- 9:05-9:25 **A digital twin platform to inform and accelerate prostate cancer trials**
 Ravi B. Parikh
 Emory University, Atlanta, GA

- 9:25-9:35 **Immune spatial organization predicts metastasis risk in aggressive localized prostate cancer***
 David D. Yang
 Brigham and Women's Hospital, Boston, MA

- 9:35-10:15 Discussion/Q&A

Break

10:15 -10:30 a.m.

**Short talks selected from proffered abstracts*

Plenary Session 2: Recent Advances in Risk, Detection, and Diagnosis

10:30 a.m. – 12:30 p.m. | Essex Ballroom

Session Chair A: *Burcu F. Darst, Fred Hutchison Cancer Center, Seattle, WA*

Session Chair B: *Franklin W. Huang, University of California San Francisco, San Francisco, CA*

- 10:30-10:35 Introduction
- 10:35-10:50 **Advances in using germline genetics to inform prostate cancer risk assessment and disease progression**
 Burcu F. Darst
- 10:50-11:10 **A framework for early interception of prostate cancer lineage plasticity**
 Sylvan C. Baca
 Dana-Farber Cancer Institute, Boston, MA
- 11:10-11:30 **AI-Driven Imaging for Prostate Cancer: Improving Detection, Risk Stratification, and Care**
 Raquel Perez-Lopez
 Vall d'Hebron Institute of Oncology, Barcelona, Spain
- 11:30-11:40 **Mosaic loss of Y chromosome and risk of prostate cancer in two U.S. cohorts***
 Anqi Wang
 Harvard T. H. Chan School of Public Health, Boston, MA
- 11:40-11:50 **Monitoring tumor evolution and phenotypic diversity in metastatic prostate cancer using liquid biopsy profiling***
 Irene Casanova-Salas
 Vall d'Hebron Institute of Oncology, Barcelona, Spain
- 11:50-12:00 **Development and validation of a semen-RNA based classifier for detection and risk stratification of prostate cancer***
 David Jarrard
 University of Wisconsin-Madison, Madison, WI
- 12:00-12:30 Discussion/Q&A

Lunch on own

12:30 - 1:45 p.m.

Plenary Session 3: Exploiting the Tumor Microenvironment and Immune Response

1:45 p.m. – 4:00 p.m. | Essex Ballroom

Session Chair A: *Lawrence Fong, Fred Hutchison Cancer Center, Seattle, WA*

Session Chair B: *Paula Hurley, Vanderbilt University Medical Center, Nashville, TN*

- 1:45-1:50 Introduction

**Short talks selected from proffered abstracts*

- 1:50-2:10 **Myeloid-mediated mechanisms of immunosuppression within the prostate cancer tumor microenvironment**
 Lawrence Fong
 Fred Hutchison Cancer Center, Seattle, WA
- 2:10-2:30 **Deconvoluting cellular interactions in prostate cancer metastatic niches that promote therapy resistance**
 Joshua M. Lang
 University of Wisconsin-Madison, Madison, WI
- 2:30-2:50 **Enhancing Androgen Receptor Antagonist-Mediated Interferon Responses in Prostate Cancer**
 Larysa Poluben
 Beth Israel Deaconess Medical Center, Boston, MA
- 2:50-3:10 **Of Nerves and Cancer**
 Gustavo E. Ayala
 Baylor College of Medicine, Houston, TX
- 3:10-3:20 **Determining the role of IFN γ signaling in neuroendocrine prostate cancer progression and immunotherapy responses***
 Katherine C. Murphy
 UMass Chan Medical School, Worcester, MA
- 3:20-4:00 Discussion/Q&A

Break

4:00 p.m. – 4:15 p.m.

Plenary Session 4: Androgen Receptor: New Insights

4:15 - 6:30 p.m. | Essex Ballroom

Session Chair A: Patrick G. Pilié, MD Anderson Cancer Center, Houston, TX

Session Chair B: Adam Sharp, The Institute of Cancer Research, Sutton, England

- 4:15-4:20 **Introduction**
- 4:20-4:40 **Balancing Act: Targeting the intersection of AR, DDR, and the tumor immune environment**
 Patrick G. Pilié
 MD Anderson Cancer Center, Houston, TX
- 4:40-5:00 **Understanding the mechanisms by which cells recognize and respond to different levels of androgens has informed new therapeutic approaches for prostate cancer**
 Donald P. McDonnell
 Duke University, Durham, NC

**Short talks selected from proffered abstracts*

- 5:00-5:20 **Androgen receptor as a tumor suppressor in castration-resistant prostate cancer**
 Laura Sena
 Johns Hopkins University, Baltimore, MD
- 5:20-5:40 **How androgen receptor structural plasticity shapes oncogenic transcriptional programs**
 Elizabeth V. Wasmuth
 University of Texas Health at San Antonio, San Antonio, TX
- 5:40-5:50 **Differential coregulator usage mediates Androgen Receptor Splice Variant 7 activity in castration resistant prostate cancer***
 Pak Lok Ivan Yu
 Vancouver Prostate Centre, Vancouver, BC, Canada
- 5:50-6:30 Discussion/ Q&A

Lightning Talks Session II

6:30 -7:00 p.m. | Essex Ballroom

Session Chair: Patrick G. Pilié, MD Anderson Cancer Center, Houston, TX

[Lightning Talks Session II Titles](#)

Reception & Poster Session B

7:00 - 9:00 p.m. | Staffordshire/ Essex North

THURSDAY, JANUARY 22

Continental Breakfast

7:00 - 8:00 am | Essex Foyer

Plenary Session 5: Genomics and Epigenomics

8:00 am-9:45 am | Essex Ballroom

Session Chair A: Massimo Loda, Weil Cornell Medicine, New York, NY

Session Chair B: Adam Sowlasky, NIH-NCI, Bethesda, MD

- 8:00-8:05 Introduction
- 8:05-8:25 **Reprogrammed metabolism fuels prostate cancer progression: therapeutic opportunities**
 Massimo Loda
 Weil Cornell Medicine, New York, NY
- 8:25-8:45 **A single-cell and spatial atlas of prostate cancer reveals the combinatorial gene programs involved in lineage plasticity and metastasis**

**Short talks selected from proffered abstracts*

Franklin W. Huang
 University of California San Francisco, San Francisco, CA

8:45-9:05 **Actionable targets in epigenetically distinct subtypes of prostate cancer**
 Michael C. Haffner
 Fred Hutchinson Cancer Center, Seattle, WA

9:05-9:15 **Deciphering the SWI/SNF complex: A crucial player in lineage plasticity and therapy resistance***
 Irene Paassen
 University of Bern, Bern, Switzerland

9:15-9:45 Discussion/ Q&A

Break

9:45-10:00 a.m.

Plenary Session 6: Targeting the Mechanisms of Treatment Resistance

9:45-11:30 a.m. | Essex Ballroom

Session Chair A: Martin E. Gleave, University of British Columbia, Vancouver, BC, Canada

Session Chair B: Leanne Woods-Burnham, Morehouse School of Medicine, Atlanta, GE

9:45-9:50 Introduction

9:50-10:10 **Genomic Landscape and Pathologic Responses to ARPI doublets vs triplets in the Genomic Umbrella Neoadjuvant Study (GUNS)**
 Martin E. Gleave
 University of British Columbia, Vancouver, BC, Canada

10:10-10:30 **Overcoming treatment resistance in aggressive variant prostate cancers, one combination at a time**
 Ana Aparicio
 MD Anderson Cancer Center, Houston, TX

10:30-10:50 **Defining the Extracellular Vesicle Proteome of Metastatic Castration Resistant Prostate Cancer Patients treated with 177Lu-PSMA-617**
 Justin Hwang
 University of Minnesota, Minneapolis, MN

10:50-11:00 **Epigenetically Informed Therapeutic Strategies for DNA-Hypomethylated Prostate Cancer***
 Pallabi Mustafi
 Fred Hutchinson Cancer Center, Seattle, WA

11:00-11:30 Discussion/Q&A

**Short talks selected from proffered abstracts*

Break

11:30-11:45 a.m.

Keynote Session 2

11:45 a.m. – 12:20 p.m. | Essex Ballroom

Session Chair: Elena Castro, Hospital Universitario 12 de Octubre, Madrid, Spain

11:45-11:50 Introduction to Keynote Speaker
 Elena Castro

11:50-12:20 **Dissecting the molecular drivers of lineage plasticity in prostate cancer**
 Charles L. Sawyers
 Memorial Sloan Kettering Cancer Center, New York, NY

Presentation of Awards to the Conference Cochairs

12:20-12:25 p.m. | Essex Ballroom

Presented by: Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY

Plenary Session 7: New Models, Targets, and Therapeutics

12:30-2:15 p.m. | Essex Ballroom

Session Chair A: Elena Castro, Hospital Universitario 12 de Octubre, Madrid, Spain

Session Chair B: Abhijit Parolia, University of Michigan, Ann Arbor, MI

12:30-12:35 Introduction

12:35-12:55 **Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity**
 Abhijit Parolia
 University of Michigan, Ann Arbor, MI

12:55-1:15 **Targeting MYC with small molecules**
 Sarki A. Abdulkadir
 Northwestern University, Chicago, IL

1:15-1:25 **Precision nutrition potentiates radiotherapy in prostate cancer***
 David P. Labbe
 McGill University, Montreal, QC, Canada

1:25-1:45 **Next Generation AR-Directed Therapies**
 Elena Castro
 Hospital Universitario 12 de Octubre, Madrid, Spain

**Short talks selected from proffered abstracts*



1:45-2:15 Discussion/Q&A

Closing Remarks and Departure

2:15 p.m.

Peter S. Nelson, Fred Hutchison Cancer Center, Seattle, WA

**Short talks selected from proffered abstracts*